首页> 外文学位 >Nutraceutical efficacy in experimental animal models of inflammatory bowel disease: Echinacea angustifolia, Prunella vulgaris and Hypericum gentianoides.
【24h】

Nutraceutical efficacy in experimental animal models of inflammatory bowel disease: Echinacea angustifolia, Prunella vulgaris and Hypericum gentianoides.

机译:在炎症性肠病实验动物模型中的营养保健功效:紫锥菊,夏枯草和龙胆金丝桃。

获取原文
获取原文并翻译 | 示例

摘要

In this study, the anti-colitic potential of Prunella vulgaris , Hypericum gentianoides, and Echinacea angustifolia were determined in the mdr1a deficient (-/-) mouse model of spontaneous colitis or the chemically induced dextran sodium sulphate (DSS) mouse model of acute colitis. Extracts of E. angustifolia root or above ground sections of P. vulgaris or H. gentianoides were extracted using the Soxhlet method in 95% ethanol and were solubilized in a final concentration of 5% ethanol for use in studies.;In the DSS model of acute colitis, E. angustifolia was not found to be effective during the period of DSS treatment (in low dose 1.75% to high dose 2.5% DSS in male and female C57BL/6 mice), or during restitution. E. angustifolia was not found to be cytotoxic in vivo. Conversely, P. vulgaris was able to significantly (p 0.05) decrease weight loss and improve macroscopic indicators of severe colitic wasting. The disparity between E. angustifolia and P. vulgaris efficacies in this acute model of colitis could be due to the difference in the constituent types found in these two extracts. E. angustifolia is composed mostly of phenolics and alkylamides, while P. vulgaris contains phenolics, flavonoids and triterpinoids. Certain types of phenols have been shown to have efficacy in low dose DSS colitis; however, flavonoids have efficacy in models of colitis as well, and in combination with phenols may be synergistic. Since flavonoids have recently proven very effective in ameliorating spontaneous colitis, P. vulgaris was also evaluated in the mdr1a-/- model of spontaneous colitis.;In the mdr1a-/- mouse model of spontaneous colitis, P. vulgaris extract treatment was compared to mdr1a-/- mice treated with 5% ethanol vehicle, metronidazole (an antibiotic and anti-colitic control) and FVBWT mice. It was discovered that P. vulgaris was able to delay onset of spontaneous colitis, significantly (p 0.05) decrease macroscopic typhlocolitic and microscopic cecal disease scores, prevent cecal neutrophil influx, and downregulate nuclear factor-kappaB (NF-kappaB) related cytokines/chemokines and gene targets. The downregulation of innate immune signals and function is hypothesized to contribute to the observed decrease in cecal tonsil CD4+ helper and CD8 + cytotoxic T cells as well as germinal center B cells. Adaptive immune function was also altered. Loss of immune tolerance to the microflora is a characteristic of chronic colitis. Unlike mdr1a-/- vehicle treated mice, which displayed antibody production to microflora antigens, P. vulgaris treated mice displayed little to no Ab response to the same microflora antigens.;H. gentianoides contains flavonoids, phenolics and a unique antimicrobial compound called uliginosin A. As the mdr1a-/- mouse model of spontaneous colitis is driven by the host immune response to the microflora and Hypericum species are known to be immunomodulatory, this extract was of interest as a therapeutic anti-colitic in the mdr1a -/- model. Onset of spontaneous colitis was significantly delayed by H. gentianoides, but was not completely abolished. Macroscopic scores, microscopic scores, serum cytokine levels and myeloperoxidase production were all significantly (p 0.05) reduced by H. gentianoides gavage. While H. gentianoides has immunosuppressant potential, a surprising increase in intestinal plasma cell infiltrate and an increase in serum IL-6 correlated with H. gentianoides gavage in mdr1a -/- mice. To date, anti-microbial functions have not been ruled out as a contributing factor in the efficacy of anti-colitic activity of this extract.;Together, these novel experiments have identified new candidates for anti-colitic therapy or therapeutic supplementation of current IBD treatment strategies. P. vulgaris, H. gentianoides and E. angustifolia merit further research as nutraceutical treatments of chronic inflammatory disorders, and these studies make it clear that synergy between phenolics, flavonoids and natural anti-bacterial compounds also warrant further research. (Abstract shortened by UMI.)
机译:在这项研究中,在自发性结肠炎的mdr1a缺陷(-/-)小鼠模型或急性结肠炎的化学诱导的葡聚糖硫酸钠(DSS)小鼠模型中确定了夏枯草,贯叶连翘和紫锥菊的抗结肠炎潜力。用索氏提取法在95%的乙醇中提取了马鞭草的根或普通地上或龙胆的地上部分的提取物,并以5%的乙醇终浓度溶解用于研究。在DSS治疗期间(在雄性和雌性C57BL / 6小鼠中,低剂量为1.75%至高剂量为2.5%DSS),或恢复期间,未发现急性大肠埃希菌有效。在体内未发现大叶肠球菌具有细胞毒性。相反地​​,寻常型腐烂假单胞菌能够显着(p <0.05)减少体重减轻并改善严重结肠炎消瘦的宏观指标。在这种急性结肠炎模型中,E。angustifolia和P. vulgaris功效之间的差异可能是由于这两种提取物中发现的成分类型不同所致。沙棘肠球菌主要由酚类和烷基酰胺类组成,而寻常疟原虫包含酚类,类黄酮和三萜类化合物。已显示某些类型的酚对低剂量DSS结肠炎有效。然而,类黄酮在结肠炎模型中也具有功效,并且与酚类组合可能具有协同作用。由于最近已证明类黄酮对改善自发性结肠炎非常有效,因此在自发性结肠炎的mdr1a-//模型中也评估了寻常性假单胞菌;在自发性结肠炎的mdr1a-//小鼠模型中,将寻常性假单胞菌提取物处理与用5%乙醇媒介物,甲硝唑(一种抗生素和抗结肠炎对照)治疗的mdr1a-/-小鼠和FVBWT小鼠。发现寻常型毕加索氏杆菌能够延缓自发性结肠炎的发作,显着(p <0.05)降低宏观盲虫性和微观盲肠疾病评分,预防盲肠中性粒细胞大量涌入,并下调核因子-κB(NF-kappaB)相关的细胞因子/趋化因子和基因靶标。假定先天免疫信号和功能的下调有助于盲肠扁桃体CD4 +辅助细胞和CD8 +细胞毒性T细胞以及生发中心B细胞的减少。适应性免疫功能也发生了改变。对微生物群的免疫耐受性丧失是慢性结肠炎的特征。与mdr1a-//-媒介物处理的小鼠表现出针对微生物菌群抗原的抗体生成不同,寻常型疟原虫处理的小鼠对相同的微生物菌群抗原表现出极少甚至没有Ab反应。龙胆中含有黄酮类化合物,酚类物质和一种独特的抗菌化合物uliginosin A。由于自发性结肠炎的mdr1a-/-小鼠模型是由宿主对菌群的免疫反应驱动的,已知金丝桃属物种具有免疫调节作用,因此该提取物具有重要的意义。 mdr1a-/-模型中的一种治疗性抗结肠炎药物。龙胆根瘤菌明显延迟了自发性结肠炎的发作,但并未完全消除。龙胆肉鼠灌胃对肉眼可见评分,微观评分,血清细胞因子水平和髓过氧化物酶产生均显着降低(p <0.05)。尽管龙胆根瘤菌具有免疫抑制剂的潜力,但肠道浆细胞浸润的惊人增加和血清IL-6的增加与mdr1a-/-小鼠中龙胆根瘤菌的管饲有关。迄今为止,尚未排除抗微生物功能是该提取物抗结肠炎活性功效的重要因素。在一起,这些新颖的实验已经确定了抗结肠炎疗法或当前IBD治疗的补充疗法的新候选人。策略。作为慢性炎症性疾病的营养保健品,体育,普通龙胆和虎杖更值得进一步研究,这些研究表明,酚类,类黄酮和天然抗菌化合物之间的协同作用也值得进一步研究。 (摘要由UMI缩短。)

著录项

  • 作者单位

    Iowa State University.;

  • 授予单位 Iowa State University.;
  • 学科 Agriculture Food Science and Technology.;Health Sciences Nutrition.;Health Sciences Immunology.
  • 学位 Ph.D.
  • 年度 2011
  • 页码 211 p.
  • 总页数 211
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:44:18

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号